If approved, biopharmaceutical critics will accuse the F.D.A. of being too closely aligned with industry. If rejected, the F.D.A will be attacked by patients and advocacy groups as preventing access to a much needed new medicine.
Biopharma Closely Watching Biden’s Pick For The Next FDA Commissioner – With Biogen Having The Most At Stake
